(19)
(11) EP 1 913 954 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.09.2012 Bulletin 2012/38

(45) Mention of the grant of the patent:
08.08.2012 Bulletin 2012/32

(21) Application number: 06794018.9

(22) Date of filing: 13.06.2006
(51) International Patent Classification (IPC): 
A61K 38/39(2006.01)
C07K 19/00(2006.01)
A61P 37/04(2006.01)
 C07K 14/78(2006.01)
C07K 14/18(2006.01)
(86) International application number:
PCT/ES2006/000343
(87) International publication number:
WO 2006/134190 (21.12.2006 Gazette 2006/51)

(54)

USE OF THE EDA DOMAIN OF FIBRONECTIN

VERWENDUNG DER EDA-DOMÄNE VON FIBRONECTIN

UTILISATION DU DOMAINE EDA DE LA FIBRONECTINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 13.06.2005 ES 200501412

(43) Date of publication of application:
23.04.2008 Bulletin 2008/17

(73) Proprietor: Proyecto de Biomedicina Cima, S.L.
31008 Pamplona Navarra (ES)

(72) Inventors:
  • LECLERC, Claude
    75015 Paris (FR)
  • LASARTE SAGASTIBELZA, Juan, José
    Avda. Pío XII, 55 E-31008 Pamplona (ES)
  • GORRAIZ AYALA, Marta
    Avda. Pío XII, 55 E-31008 Pamplona (ES)
  • PRIETO VALTUEÑA, Jesús
    Avda. Pío XII, 55 E-31008 Pamplona (ES)

(74) Representative: Ungria Lopez, Javier et al
Avda. Ramón y Cajal, 78
28043 Madrid
28043 Madrid (ES)


(56) References cited: : 
EP-A1- 1 188 446
WO-A2-00/76456
 WO-A1-03/070761
US-A- 5 108 898
   
  • SAITO S ET AL: "The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 22 OCT 1999 LNKD- PUBMED:10521465, vol. 274, no. 43, 22 October 1999 (1999-10-22), pages 30756-30763, XP002612109, ISSN: 0021-9258
  • OKAMURA Y. ET AL.: 'The extra domain A of fibronectin activates Toll-like receptor 4' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 276, no. 13, March 2001, pages 10229 - 10233, XP003008523
  • PAOLELLA G. ET AL.: 'Sequence analysis and in vivo expression show that alternative splicing of ED-B and ED-A regions of the human fibronectin gene are independent events' NUCLEIC ACIDS RESEARCH vol. 16, no. 8, April 1988, pages 3545 - 3557, XP000910295
  • KAISHO T. ET AL.: 'Toll-like receptors as adjuvant receptors' BIOCHIMICA ET BIOPHYSICA ACTA vol. 1589, no. 1, February 2002, pages 1 - 13, XP004344849
  • MURO A.F. ET AL.: 'Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and 5' splicing site' FEBS LETTERS vol. 437, no. 1-2, 1998, pages 137 - 141, XP004258506
  • LUTZ M. ET AL.: 'Immature, semi-immature and fully mature dendritic cells: which signals induce tolerance or immunity?' TRENDS IN IMMUNOLOGY vol. 23, no. 9, September 2002, pages 445 - 449, XP004377436
  • MARTIN P. ET AL.: 'Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in Hepatitis C virus NS3 antigen' JOURNAL OF MEDICAL VIROLOGY vol. 74, no. 3, November 2004, pages 397 - 405, XP008078477
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).